Loading company…
Mercy BioAnalytics develops blood-based tests for early cancer detection using extracellular vesicles.
Mercy BioAnalytics develops the Halo blood test to detect cancers, including ovarian and lung cancer, by analyzing extracellular vesicles. Its assay examines surface proteins that indicate the tumor cell of origin and uses a PCR-based readout. Founded in 2018, the company is based in Waltham, US. It raised USD 59 million in Series B funding in September 2025, co-led by Novalis LifeSciences and Sozo Ventures, to expand the Mercy Halo portfolio.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in